Side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation
It's a critical tool for any serious lab
This event-driven superiority trial randomised 9,650 adults with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease to oral semaglutide 14 mg or placebo
Medicare has historically excluded weight-loss drugs by statute, though the Medicare GLP-1 Bridge demonstration (announced for July 2026) is set to cover Wegovy and Zepbound for eligible Part D beneficiaries at a $50/month copay, with the longer-term BALANCE Model launching in Part D in January 2027
Understanding the distinction between these treatments is crucial for aesthetics professionals seeking to elevate their practice
There will be no particles and no cloudiness